Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

• Published in: Nature communications Vol. 14; no. 1; pp. 3605 - 9
• Main Authors: Follmann, Dean, O’Brien, Meagan P., Fintzi, Jonathan, Fay, Michael P., Montefiori, David, Mateja, Allyson, Herman, Gary A., Hooper, Andrea T., Turner, Kenneth C., Chan, Kuo- Chen, Forleo-Neto, Eduardo, Isa, Flonza, Baden, Lindsey R., El Sahly, Hana M., Janes, Holly, Doria-Rose, Nicole, Miller, Jacqueline, Zhou, Honghong, Dang, Weiping, Benkeser, David, Fong, Youyi, Gilbert, Peter B., Marovich, Mary, Cohen, Myron S.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 17.06.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 2019-nCoV Vaccine mRNA-1273; 631/250/2152/2153/1291; 631/326/590/2293; 631/326/596/4130; 692/699/255/2514; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; Correlation; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; Effectiveness; Humanities and Social Sciences; Humans; Monoclonal antibodies; mRNA; multidisciplinary; Neutralizing; Prevention; SARS-CoV-2; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccines

While new vaccines for SARS-CoV-2 are authorized based on neutralizing antibody (nAb) titer against emerging variants of concern, an analogous pathway does not exist for preventative monoclonal antibodies. In this work, nAb titers were assessed as correlates of protection against COVID-19 in the cas...